ToolGen

Main focus: Genetic diseases and next-generation CAR-T therapies

Company stage: Clinical

Diseases: Charcot-Marie-Tooth Disease, Age-related Macular Degeneration, Hemophilia B, cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Public (KOSDAQ:199800)

Location: Geumcheon-gu, Seoul, South Korea

Website: http://www.toolgen.com/eng/index.jsp

Pipeline: http://www.toolgen.com/eng/business/business_03.jsp

Gene editing Partnerships: mCureX Therapeutics

ToolGen holds multiple patents within the gene-editing space and is currently developing several in vivo and ex vivo-based programmes. The company is currently advancing a next-generation gene-edited CAR-T programme, which is being tested in clinical trials. The company also has multiple programmes under development for the treatment of genetic diseases.

ToolGen

Your Latest CMN News

Minimal Cas9 ancestor enables durable epigenetic...

CMN Briefs

May. 8, 2025

Feng Zhang and colleagues report that the engineering of a compact RNA-guided nuclease, NovaIscB, derived from the OMEGA system enables efficient and...

Breaking: CRISPR Gene Activation Rescues Neuronal...

CMN Interview

May. 7, 2025

A new study using CRISPR activation in a cortical organoid model offers promise for treating a rare genetic epileptic disorder. The novel approach –...

TXNIP affects stress pathways without boosting...

CMN Briefs

May. 6, 2025

TXNIP, a key regulator of oxidative and endoplasmic reticulum (ER) stress with established roles in diabetes, cardiovascular disease, cancer, and...

Highlight: CRISPR Screen Identifies SFRP1 as Key...

CMN Briefs

May. 5, 2025

Researchers have identified a secreted protein that acts as a crucial brake on skin stem cell proliferation, offering new insights into maintaining...

CMN Weekly (2 May 2025) - Your Weekly CRISPR...

CMN Weekly

May. 2, 2025

Some of the best links we picked up around the internet